Cambridge Cognition and world-class imaging company, IXICO were awarded a grant from the Government-funded Biomedical Catalyst to build and test a prototype national dementia early diagnosis service, aiming to reduce time to diagnosis from 18 months to 3 months. The advanced imaging and testing technologies combined by IXICO and Cambridge Cognition provide a decision support tool for early diagnosis of dementia. It is hoped that by providing easy to understand, actionable information for health care providers, including GPs, will lead to rapid treatment and support for British dementia patients.
GPs in the test area will refer patients who need further assessment for possible dementia to one of two Brain Health Centre types – one based in a hospital Memory Clinic (located at The Maudsley Hospital, part of South London and Maudsley NHS Foundation Trust), and the second a mobile community based service, which might be parked outside local health centres ensuring convenience for patients and their families. GPs will have already ensured that only patients who need further investigation are referred to the community Brain Health Centres by using Cambridge Cognition’s new CANTABmobile™ software on an iPad, which, in less than 10 minutes, differentiates between patients with normal and abnormal memory.
The Brain Health Centres combine cutting edge digital technologies, previously only available to pharmaceutical companies conducting expensive clinical trials, and aims to make this available cost-effectively to all patients being investigated for possible dementia in the NHS.
The company turned to creative marketing specialists, KISS Communications to brand the new Brain Health Centre and develop an interim web site .
Simon Fryer, CEO of KISS Communications, said, “Cambridge Cognition is a fantastic, innovative company to work with and we are very proud to have a small part in the roll out of this transformational world leading technology”.
Simon Merritt, Marketing Director at Cambridge Cognition said, “KISS were quick to understand the brief and operationalise their work to a very challenging timeframe."
About KISS Communications
KISS Communications is the integrated agency built on the philosophy of keeping things simple. Our experienced team energise brands that aspire to be number one in their category, gain distribution and increase sales around the world.
We provide strategy, advertising, design, branding, digital, exhibition and public relations services. The KISS guiding principles are to have a lack of unnecessary complexity in everything we do whilst delivering maximum effect with minimum means.
The agency has won an impressive number of blue chip clients, including Anglian Water, Bokomo Foods UK, PlastiKote, Booking.com, Johnson Matthey, Bosch, SISK and Maersk, and successful SMEs including One Nucleus, Balancing Blooms, Horizon Discovery, IMRG, Real-Status, Intergence, and Cambridge Past, Present & Future.
For further information, please contact:
Justine Smith / Laura Brown
T: 01223 911 123 or 0208 12345 75
natalie_job@kisscom.co.uk / laura@kisscom.co.uk
About IXICO:
IXICO Ltd is a leading medical imaging company that provides software solutions and services to deliver imaging biomarkers in clinical trials, research studies and health care diagnostics.
IXICO’s clinical trial technologies include its TrialWire™ electronic data transfer portal and its TrialTracker™ Image Management System. This technology optimises imaging trial workflows and ensures regulatory compliant image handling for clinical trials. It also provides a platform for imaging informatics and is deployed at major UK academic institutions. IXICO’s quantitative brain image analysis platform quantifies brain atrophy for research purposes, and pending medical device approval, provides a decision support tool for the diagnosis of dementia within the EU. This technology can transform the diagnostic process in healthcare and enable health care providers to offer better care to patients and their families by identifying people at risk of developing disease and monitoring disease progression. IXICO is committed to developing solutions for the diagnosis of dementia and other neurological diseases as stand-alone tools and in combination with other technologies.
As a full service Imaging Contract Research Organisation (ICRO), IXICO offers comprehensive capabilities with global reach predominantly in the CNS, Oncology and Musculoskeletal fields and across all major imaging modalities. IXICO provides a variety of central assessments that can be used as imaging endpoints in clinical trials to assess subject eligibility and drug safety and efficacy, and has designed its systems to address the critical areas of imaging in clinical trials from data acquisition to image analysis and reporting.
About Cambridge Cognition:
Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company’s range of touch-screen CANTAB™ neuropsychological tests, originating from work at the University of Cambridge, and highly validated in several hundred peer-review publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the CANTAB Mobile brand, which will improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients in order that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care – leading to better outcomes for patients and their families.
About CANTABmobile™:
CANTABmobile™ is a new assessment for memory aimed at GPs and physicians in hospitals that was launched by Cambridge Cognition in May 2012. It is medical software that is downloaded onto an iPad in the form of an App, and helps GPs to understand whether a patient has a clinically relevant memory problem comparing the test results to a stored database within the App of over 5000 patients. Currently available with over 20 languages, the product is being piloted within a variety of clinical and community settings within the NHS and deployed in a number of Clinical Commissioning Groups. For further information: www.cantabmobile.com
_________________________________________